Octagon Capital Advisors LP
13F filer · CIK 0001839435Reported Aug 14, 2026
Net seller this quarter
13F portfolio value$1.11BU.S. long equity reported on 13F
Positions264 new · 7 closed
Net flow last quarter-$40.1MBuys minus sells
Top 10 positions weight78.5%Concentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q2 2026Reported Aug 14, 202626 positions | |||||
| $180M | 16.14% | 3.36% | -5.4% | Q3 2023 | |
| $139M | 12.47% | 2.20% | +20.9% | Q1 2026 | |
| $132M | 11.89% | 1.26% | +46.7% | Q1 2025 | |
| $90.9M | 8.17% | 1.37% | Not reported | Q3 2024 | |
| $79.7M | 7.16% | Not reported | Not reported | Q4 2025 | |
| $68.5M | 6.15% | 4.08% | Not reported | Q1 2024 | |
| $66M | 5.93% | 2.98% | +9.4% | Q4 2020 | |
| $42.8M | 3.85% | 3.82% | Not reported | Q4 2025 | |
| $39.7M | 3.57% | 0.52% | Not reported | Q3 2022 | |
| $35.5M | 3.20% | 0.37% | -27.1% | Q2 2021 | |
| $31M | 2.78% | 1.80% | Not reported | Q1 2026 | |
| $29.6M | 2.66% | 0.51% | Not reported | Q1 2026 | |
| $21.5M | 1.93% | 5.92% | Not reported | Q4 2025 | |
| $20.4M | 1.83% | 0.94% | -34.5% | Q1 2024 | |
| $19.7M | 1.78% | 0.70% | Not reported | Q2 2023 | |
| $18.2M | 1.64% | 0.16% | New | Q2 2026 | |
| $15.8M | 1.42% | 0.70% | +176.8% | Q3 2024 | |
| $10.7M | 0.97% | Not reported | New | Q2 2026 | |
| $10.6M | 0.95% | 5.11% | -39.6% | Q4 2025 | |
| $9.42M | 0.85% | 0.19% | Not reported | Q2 2025 | |
| $9.03M | 0.81% | 1.40% | New | Q2 2026 | |
| $6.29M | 0.57% | 0.90% | New | Q2 2026 | |
| $5.87M | 0.53% | 0.22% | -78.8% | Q1 2025 | |
| $4.69M | 0.42% | 3.59% | Not reported | Q3 2024 | |
| $1.69M | 0.15% | 3.32% | -41.9% | Q1 2026 | |
| $1.28M | 0.11% | 1.59% | Not reported | Q4 2020 | |
| Q1 2026Reported May 15, 202629 positions | |||||
| $163M | 18.08% | 3.57% | -19.5% | Q3 2023 | |
| $90.5M | 10.01% | 1.38% | Not reported | Q3 2024 | |
| $75.4M | 8.34% | 0.86% | -10.5% | Q1 2025 | |
| $62.4M | 6.90% | Not reported | +11.9% | Q4 2025 | |
| $46.1M | 5.10% | 2.35% | New | Q1 2026 | |
| $45.5M | 5.03% | 4.35% | Not reported | Q1 2024 | |
| $39.6M | 4.38% | 3.08% | Not reported | Q4 2020 | |
| $35.4M | 3.92% | 0.52% | -20.6% | Q2 2021 | |
| $31.3M | 3.46% | 0.56% | Not reported | Q3 2022 | |
| $30.6M | 3.38% | 3.94% | +9.4% | Q4 2025 | |
| CPCNTACentessa Pharmaceuticals PLC | $29.8M | 3.30% | 0.48% | Not reported | Q1 2023 |
| KPKALVKalVista Pharmaceuticals, Inc. | $29.2M | 3.23% | 2.83% | +13.9% | Q4 2024 |
| $28.5M | 3.15% | 0.51% | New | Q1 2026 | |
| TPTERNTerns Pharmaceuticals, Inc. | $27.9M | 3.09% | 0.46% | Not reported | Q1 2024 |
| $26.8M | 2.97% | 1.45% | +20.7% | Q1 2024 | |
| $18M | 1.99% | 6.14% | +7.4% | Q4 2025 | |
| $17.7M | 1.96% | 1.16% | -47.3% | Q1 2025 | |
| $17.3M | 1.91% | 0.71% | Not reported | Q2 2023 | |
| $17.2M | 1.90% | 1.80% | New | Q1 2026 | |
| $13.8M | 1.52% | 5.71% | New | Q1 2026 | |
| $12.3M | 1.36% | 8.67% | +16.6% | Q4 2025 | |
| $12M | 1.33% | 0.19% | Not reported | Q2 2025 | |
| $6.58M | 0.73% | 3.96% | Not reported | Q3 2024 | |
| $6.44M | 0.71% | 0.90% | -31.1% | Q1 2024 | |
| $6.31M | 0.70% | 1.48% | -36.2% | Q4 2025 | |
| $4.66M | 0.52% | 0.25% | -75.4% | Q3 2024 | |
| $3.3M | 0.37% | 0.69% | Not reported | Q1 2024 | |
| $3.3M | 0.37% | 0.40% | -71.3% | Q4 2025 | |
| $2.55M | 0.28% | 3.30% | -44.3% | Q4 2020 | |
| Q4 2025Reported Feb 17, 202626 positions | |||||
| $102M | 12.38% | 0.96% | -42.9% | Q1 2025 | |
| $99.6M | 12.09% | 5.59% | Not reported | Q3 2023 | |
| $83.5M | 10.13% | 1.46% | -18.2% | Q3 2024 | |
| $48.7M | 5.92% | 3.11% | -2.3% | Q4 2020 | |
| $43.1M | 5.24% | 5.96% | -18.4% | Q4 2020 | |
| $41.6M | 5.05% | 0.66% | +48.6% | Q2 2021 | |
| $39.7M | 4.81% | 4.64% | Not reported | Q1 2024 | |
| $35.2M | 4.28% | 2.19% | Not reported | Q1 2025 | |
| $31.9M | 3.87% | 1.22% | 0.0% | Q1 2024 | |
| $29.9M | 3.63% | Not reported | +4.7% | Q1 2024 | |
| $24.7M | 3.00% | Not reported | New | Q4 2025 | |
| $22.5M | 2.73% | 6.00% | New | Q4 2025 | |
| CTCDTXCidara Therapeutics, Inc. | $22.1M | 2.68% | 0.32% | Not reported | Q3 2025 |
| $21.1M | 2.57% | 4.27% | New | Q4 2025 | |
| KPKALVKalVista Pharmaceuticals, Inc. | $20.6M | 2.50% | 2.50% | Not reported | Q4 2024 |
| RTRAPTRAPT Therapeutics, Inc. | $19.4M | 2.36% | 2.07% | Not reported | Q4 2023 |
| CPCNTACentessa Pharmaceuticals PLC | $18.8M | 2.28% | 0.50% | -9.6% | Q1 2023 |
| $18.6M | 2.26% | 1.03% | -7.1% | Q3 2024 | |
| $17.1M | 2.08% | 2.36% | New | Q4 2025 | |
| $13.1M | 1.59% | 1.30% | Not reported | Q1 2024 | |
| $11M | 1.34% | 0.34% | -43.6% | Q2 2025 | |
| $8.56M | 1.04% | 1.59% | New | Q4 2025 | |
| $7.98M | 0.97% | 7.96% | New | Q4 2025 | |
| $7.77M | 0.94% | 5.42% | -14.4% | Q1 2024 | |
| $5.77M | 0.70% | 4.52% | Not reported | Q3 2024 | |
| $4.56M | 0.55% | 1.02% | Not reported | Q1 2024 | |
| Q3 2025Reported Nov 14, 202525 positions | |||||
| $112M | 17.05% | 2.09% | +4.6% | Q1 2025 | |
| $95.1M | 14.41% | 5.64% | +3.2% | Q3 2023 | |
| $44.8M | 6.80% | 7.37% | -7.1% | Q4 2020 | |
| $41.3M | 6.26% | 2.06% | +4.0% | Q3 2024 | |
| $36.4M | 5.51% | 4.82% | +1.3% | Q1 2024 | |
| $30.7M | 4.65% | 1.50% | +8.2% | Q1 2024 | |
| $29.7M | 4.49% | 3.31% | -28.0% | Q4 2020 | |
| MMRUSMerus N.V. | $29M | 4.40% | 0.41% | -20.8% | Q1 2021 |
| $25.8M | 3.90% | 2.20% | -23.3% | Q1 2025 | |
| $25.1M | 3.81% | Not reported | Not reported | Q1 2024 | |
| APAPLSApellis Pharmaceuticals, Inc. | $20.4M | 3.10% | 0.71% | Not reported | Q4 2020 |
| $20.4M | 3.09% | 0.50% | +35.3% | Q2 2021 | |
| CPCNTACentessa Pharmaceuticals PLC | $20.1M | 3.05% | 0.62% | -19.4% | Q1 2023 |
| $18M | 2.73% | 1.33% | +7.4% | Q3 2024 | |
| KPKALVKalVista Pharmaceuticals, Inc. | $15.5M | 2.35% | 2.52% | Not reported | Q4 2024 |
| $14.1M | 2.14% | 8.90% | Not reported | Q1 2024 | |
| $12.1M | 1.83% | 1.32% | +317.2% | Q1 2024 | |
| $10.2M | 1.54% | 0.74% | Not reported | Q2 2025 | |
| $10.1M | 1.54% | 0.81% | -65.1% | Q4 2023 | |
| CTCDTXCidara Therapeutics, Inc. | $9.58M | 1.45% | 0.34% | New | Q3 2025 |
| $4.61M | 0.70% | 0.37% | Not reported | Q1 2025 | |
| $4.37M | 0.66% | 1.71% | -16.8% | Q3 2024 | |
| $4.36M | 0.66% | 4.80% | Not reported | Q3 2024 | |
| $3.23M | 0.49% | 2.13% | Not reported | Q1 2024 | |
| $3.22M | 0.49% | 0.06% | Not reported | Q1 2023 | |
Premium opens every quarter this fund has filed